<p>迈阿密 --（商业资讯）--Summit Therapeutics Inc.（纳斯达克：SMMT）（“Summit”，“我们” 或 “公司”）今天宣布授予诱导奖励，授予购买总计高达 67,483 股普通股的期权。这些奖励授予了公司九名新员工。根据纳斯达克上市规则 5635(c)(4)，这些奖励作为新员工成为公司员工的诱导材料，并已获得公司薪酬委员会的批准。诱导奖励于 2025 年 12 月 2 日授予。期权的有效期为十（10）年，行使价格为每股 17.25 美元，这是公司普通股在 2025 年 12 月 2 日由纳斯达克报告的收盘价。期权是从薪酬委员会于 2025 年 1 月 22 日保留的股权激励池中授予的，作为对新员工的诱导，符合纳斯达克上市规则 5635(c)(4)。</p>
<p>授予受益人的期权须在四年内以相等的年度分期归属。授予的期权须遵循受赠人将签署的股票期权协议的条款。</p>
<p><strong>关于 Summit Therapeutics</strong></p>
<p>Summit Therapeutics Inc.是一家生物制药肿瘤公司，专注于发现、开发和商业化以患者、医生、护理人员和社会为中心的药物疗法，旨在改善生活质量、延长潜在寿命并解决严重的未满足医疗需求。</p>
<p>Summit 成立于 2003 年，我们的股票在纳斯达克全球市场上市（代码 “SMMT”）。我们总部位于佛罗里达州迈阿密，并在加利福尼亚州门洛帕克和英国牛津设有其他办公室。</p>
<p>欲了解更多信息，请访问 https://www.smmttx.com 并在 X 上关注我们 @SMMT_TX。</p>
<p><strong>Summit 前瞻性声明</strong></p>
<p>本新闻稿中关于公司未来期望、计划和前景的任何声明，包括但不限于关于公司产品候选者的临床和前临床开发、与 Akeso Inc.的合作关系的进入及相关行动、私人配售的净收益的预期用途、公司预期支出和现金流、公司产品候选者的治疗潜力、公司产品候选者的潜在商业化、临床试验的启动、完成和数据可用性的时间、潜在的市场批准申请提交、BLA 提交的预期时间、潜在收购、关于之前披露的市场股权发行计划（“ATM 计划”）的声明、预期收益及其用途、公司关于基于股票的补偿的估计，以及包含 “预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“可能”、“计划”、“潜在”、“预测”、“项目”、“应该”、“目标”、“会” 等类似表达的其他声明，构成 1995 年《私人证券诉讼改革法》意义上的前瞻性声明。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果有重大差异，包括公司在 ATM 计划下出售普通股的能力、影响资本市场的条件、一般经济、行业或政治条件，包括地缘政治发展的影响、国内和国际贸易政策及货币政策、我们对 ivonescimab 开发和商业化活动相关基础数据的评估结果、与监管机构（包括食品和药物管理局）的讨论结果、未来临床试验启动的固有不确定性、正在进行和未来临床试验的数据可用性和时间、这些试验的结果及其成功、可能影响我们临床试验和运营时间及状态的全球公共卫生危机、临床试验的初步结果是否会预测该试验的最终结果，或早期临床试验或前临床研究的结果是否会指示后期临床试验的结果、是否会出现扩展公司药物候选者管道的商业发展机会，包括但不限于通过潜在收购和/或与其他实体的合作，监管批准的预期、影响政府合同和资金奖励的法律法规、公司可预见和不可预见的运营费用和资本支出需求的资金可用性，以及公司向证券交易委员会提交的文件中 “风险因素” 和 “管理层对财务状况和经营结果的讨论与分析” 部分讨论的其他因素。对我们正在进行的试验的任何变更可能导致延迟，影响我们未来的支出，并增加我们商业化努力的不确定性，以及影响 ivonescimab 临床开发成功完成的可能性。因此，读者不应对前瞻性声明或信息过于依赖。此外，本新闻稿中包含的任何前瞻性声明仅代表公司在本声明日期的观点，不应被视为公司在任何后续日期的观点。公司特别声明不承担更新本新闻稿中包含的任何前瞻性声明的义务。</p>
<p>Summit Therapeutics 及其标志是 Summit Therapeutics Inc.的商标。</p>
<p>版权 2025，Summit Therapeutics Inc.保留所有权利。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMDUxMTkxOTJyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMDUxMTkxOTJyMQ"/></p>
<p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20251205119192/en/</p>
<p><strong>联系 Summit 投资者关系：</strong></p>
<p>Dave Gancarz</p>
<p>首席商务与战略官</p>
<p>Nathan LiaBraaten</p>
<p>投资者关系高级总监</p>
<p>investors@smmttx.com</p>
<p>media@smmttx.com</p>
<p>来源：Summit Therapeutics</p>

Summit治疗

<p>Summit Therapeutics 宣布根据纳斯达克上市规则 5635(c)(4) 向九名新员工授予购买 67,483 股普通股的期权激励。该期权的有效期为十年，行使价格为每股 17.25 美元，并在四年内逐步归属。Summit Therapeutics 是一家生物制药肿瘤学公司，专注于开发改善生活质量和满足未满足医疗需求的疗法</p>

<p>MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (&#34;Summit,&#34; &#34;we,&#34; or the &#34;Company&#34;) today announced the grant of inducement awards of options to purchase a collective total of up to 67,483 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committee. The inducement awards were granted on December 2, 2025. The options have a ten (10) year term and an exercise price of $17.25 per share, the closing price per share of the Company’s common stock as reported by Nasdaq on December 2, 2025. The options were granted from a pool of equity incentives reserved by the Compensation Committee on January 22, 2025 for issuance as inducements to new employees in accordance with Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>迈阿密 --（商业资讯）--Summit Therapeutics Inc.（纳斯达克：SMMT）（“Summit”，“我们” 或 “公司”）今天宣布授予诱导奖励，授予购买总计高达 67,483 股普通股的期权。这些奖励授予了公司九名新员工。根据纳斯达克上市规则 5635(c)(4)，这些奖励作为新员工成为公司员工的诱导材料，并已获得公司薪酬委员会的批准。诱导奖励于 2025 年 12 月 2 日授予。期权的有效期为十（10）年，行使价格为每股 17.25 美元，这是公司普通股在 2025 年 12 月 2 日由纳斯达克报告的收盘价。期权是从薪酬委员会于 2025 年 1 月 22 日保留的股权激励池中授予的，作为对新员工的诱导，符合纳斯达克上市规则 5635(c)(4)。</p>
</div><p>The options awarded to the recipients are subject to vesting in equal annual installments over a four-year period. The options awarded are subject to the terms of a stock option agreement to be executed by the recipient of the grant.</p>
<div class="lb-trans"><p>授予受益人的期权须在四年内以相等的年度分期归属。授予的期权须遵循受赠人将签署的股票期权协议的条款。</p>
</div><p><strong>About Summit Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Summit Therapeutics</strong></p>
</div><p>Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.</p>
<div class="lb-trans"><p>Summit Therapeutics Inc.是一家生物制药肿瘤公司，专注于发现、开发和商业化以患者、医生、护理人员和社会为中心的药物疗法，旨在改善生活质量、延长潜在寿命并解决严重的未满足医疗需求。</p>
</div><p>Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol &#34;SMMT&#34;). We are headquartered in Miami, Florida, and we have additional offices in Menlo Park, California, and Oxford, UK.</p>
<div class="lb-trans"><p>Summit 成立于 2003 年，我们的股票在纳斯达克全球市场上市（代码 “SMMT”）。我们总部位于佛罗里达州迈阿密，并在加利福尼亚州门洛帕克和英国牛津设有其他办公室。</p>
</div><p>For more information, please visit https://www.smmttx.com and follow us on X @SMMT_TX.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 https://www.smmttx.com 并在 X 上关注我们 @SMMT_TX。</p>
</div><p><strong>Summit Forward-looking Statements</strong></p>
<div class="lb-trans"><p><strong>Summit 前瞻性声明</strong></p>
</div><p>Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company’s product candidates, entry into and actions related to the Company’s partnership with Akeso Inc., the intended use of the net proceeds from the private placements, the Company's anticipated spending and cash runway, the therapeutic potential of the Company’s product candidates, the potential commercialization of the Company’s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the expected timing of BLA submissions, potential acquisitions, statements about the previously disclosed At-The-Market equity offering program (“ATM Program”), the expected proceeds and uses thereof, the Company’s estimates regarding stock-based compensation, and other statements containing the words &#34;anticipate,&#34; &#34;believe,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;should,&#34; &#34;target,&#34; &#34;would,&#34; and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company’s ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets, general economic, industry, or political conditions, including the effects of geopolitical developments, domestic and foreign trade policies, and monetary policies, the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, global public health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company’s pipeline of drug candidates, including without limitation, through potential acquisitions of, and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the &#34;Risk Factors&#34; and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of filings that the Company makes with the Securities and Exchange Commission. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.</p>
<div class="lb-trans"><p>本新闻稿中关于公司未来期望、计划和前景的任何声明，包括但不限于关于公司产品候选者的临床和前临床开发、与 Akeso Inc.的合作关系的进入及相关行动、私人配售的净收益的预期用途、公司预期支出和现金流、公司产品候选者的治疗潜力、公司产品候选者的潜在商业化、临床试验的启动、完成和数据可用性的时间、潜在的市场批准申请提交、BLA 提交的预期时间、潜在收购、关于之前披露的市场股权发行计划（“ATM 计划”）的声明、预期收益及其用途、公司关于基于股票的补偿的估计，以及包含 “预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“可能”、“计划”、“潜在”、“预测”、“项目”、“应该”、“目标”、“会” 等类似表达的其他声明，构成 1995 年《私人证券诉讼改革法》意义上的前瞻性声明。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果有重大差异，包括公司在 ATM 计划下出售普通股的能力、影响资本市场的条件、一般经济、行业或政治条件，包括地缘政治发展的影响、国内和国际贸易政策及货币政策、我们对 ivonescimab 开发和商业化活动相关基础数据的评估结果、与监管机构（包括食品和药物管理局）的讨论结果、未来临床试验启动的固有不确定性、正在进行和未来临床试验的数据可用性和时间、这些试验的结果及其成功、可能影响我们临床试验和运营时间及状态的全球公共卫生危机、临床试验的初步结果是否会预测该试验的最终结果，或早期临床试验或前临床研究的结果是否会指示后期临床试验的结果、是否会出现扩展公司药物候选者管道的商业发展机会，包括但不限于通过潜在收购和/或与其他实体的合作，监管批准的预期、影响政府合同和资金奖励的法律法规、公司可预见和不可预见的运营费用和资本支出需求的资金可用性，以及公司向证券交易委员会提交的文件中 “风险因素” 和 “管理层对财务状况和经营结果的讨论与分析” 部分讨论的其他因素。对我们正在进行的试验的任何变更可能导致延迟，影响我们未来的支出，并增加我们商业化努力的不确定性，以及影响 ivonescimab 临床开发成功完成的可能性。因此，读者不应对前瞻性声明或信息过于依赖。此外，本新闻稿中包含的任何前瞻性声明仅代表公司在本声明日期的观点，不应被视为公司在任何后续日期的观点。公司特别声明不承担更新本新闻稿中包含的任何前瞻性声明的义务。</p>
</div><p>Summit Therapeutics and the Summit Therapeutics logo are trademarks of Summit Therapeutics Inc.</p>
<div class="lb-trans"><p>Summit Therapeutics 及其标志是 Summit Therapeutics Inc.的商标。</p>
</div><p>Copyright 2025, Summit Therapeutics Inc. All Rights Reserved</p>
<div class="lb-trans"><p>版权 2025，Summit Therapeutics Inc.保留所有权利。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMDUxMTkxOTJyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251205119192r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251205119192/en/</p>
<div class="lb-trans"><p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20251205119192/en/</p>
</div><p><strong>Contact Summit Investor Relations:</strong></p>
<div class="lb-trans"><p><strong>联系 Summit 投资者关系：</strong></p>
</div><p>Dave Gancarz</p>
<div class="lb-trans"><p>Dave Gancarz</p>
</div><p>Chief Business &amp; Strategy Officer</p>
<div class="lb-trans"><p>首席商务与战略官</p>
</div><p>Nathan LiaBraaten</p>
<div class="lb-trans"><p>Nathan LiaBraaten</p>
</div><p>Senior Director, Investor Relations</p>
<div class="lb-trans"><p>投资者关系高级总监</p>
</div><p>investors@smmttx.com</p>
<div class="lb-trans"><p>investors@smmttx.com</p>
</div><p>media@smmttx.com</p>
<div class="lb-trans"><p>media@smmttx.com</p>
</div><p>Source: Summit Therapeutics</p>
<div class="lb-trans"><p>来源：Summit Therapeutics</p>
</div>

Summit 治疗公司根据纳斯达克上市规则 5635(c)(4) 报告了诱导性授予 | SMMT 股票新闻